Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (mBC) at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Company to Host Investor Event on June 3, 2018

Morris Plains, New Jersey, UNITED STATES

MORRIS PLAINS, N.J., April 25, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leader in the field of antibody-drug conjugates (ADCs), today announced that its abstract on Phase 2 results of sacituzumab govitecan in patients with HR+, human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) has been selected for oral presentation at the 2018 ASCO Annual Meeting, scheduled for June 1-5, 2018 at McCormick Place Convention Center in Chicago, Illinois.

“We are very excited about the opportunity to present our new data for sacituzumab govitecan in treatment-refractory HR+ metastatic breast cancer, a patient population with the distinct need for better treatment options,” stated Robert Iannone, M.D., M.S.C.E, Head of Research & Development and Chief Medical Officer. “Breast cancer is an area of key strategic focus for Immunomedics, as reflected by the implementation of our respective development plans. We are planning for our first breast cancer indication in patients with metastatic triple-negative breast cancer for which we will submit a Biologics License Application to the Food and Drug Administration by the end of May 2018 for accelerated approval in the third-line setting.”

Details of the oral presentation at ASCO are:

Sunday, June 3, 2018

  • Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone receptor-positive (HR+)/HER2- metastatic breast cancer (mBC) (Bardia, et al.)
    Session Title: Breast Cancer – Metastatic
    Abstract # 1004
    9:12 a.m. - 9:24 a.m. (Central Time)
    Hall D2

Investor Event
On June 3, 2018, Immunomedics will host an investor event at 5:00 p.m. Central Time at the McCormick Place Convention Center in Chicago, IL. For additional information and/or to RSVP for the event, please contact Dr. Chau Cheng at The investor event will be webcast via the Investors page on the Company’s website at

About Immunomedics
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases. Immunomedics’ corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates. To that end, Immunomedics’ immediate priority is to commercialize its most advanced product candidate, sacituzumab govitecan (IMMU-132), beginning in the U.S., with metastatic triple-negative breast cancer as the first indication. For additional information on the Company, please visit its website at The information on its website does not, however, form a part of this press release.

Cautionary note regarding forward-looking statements
This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, anticipated patient enrollment, trial outcomes, timing or associated costs), regulatory applications and related timelines, including the anticipated filing timeline for the BLA, out-licensing arrangements, forecasts of future operating results, potential collaborations, and capital raising activities, timing for bringing any product candidate to market, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, the Company’s dependence on business collaborations or availability of required financing from capital markets, or other sources on acceptable terms, if at all, in order to further develop our products and finance our operations, new product development (including clinical trials outcome and regulatory requirements/actions), the risk that we or any of our collaborators may be unable to secure regulatory approval of and market our drug candidates, risks associated with the outcome of pending litigation and competitive risks to marketed products, and the Company’s ability to repay its outstanding indebtedness, if and when required, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. 

For More Information:
Dr. Chau Cheng
Senior Director, Investor Relations & Corporate Secretary
(973) 605-8200, extension 123